Table 1 Baseline demographic and clinical features of RA, OA and Orth.A patients in the study of synovial PGC-1β by immunohistochemistry
Characteristic | RA patients (n = 31) | OA patients (n = 13) | Orth.A patients (n = 10) |
|---|---|---|---|
Demographic | Â | Â | Â |
Age, yrs, median (IQR) | 61 (53 to 66) | 61 (56 to 65) | 32 (25 ~ 44) |
Female, n (%) | 24 (77.4) | 11 (84.6) | 5 (50.0) |
Disease status | Â | Â | Â |
Disease duration, mo, median (IQR) | 36 (12 to 120) | 60 (24 to 114) | 3 (1 to 39) |
ESR, mm/h, median (IQR) | 82 (50 to 108) | 18 (11 to 33) | 14 (5 to 38) |
CRP, mg/dl, median (IQR) | 4.28 (1.89 to 6.05) | 0.33 (0.25 to 0.93) | 0.19 (0.08 to 0.34) |
Rheumatoid factor-positive, n (%) | 28 (90.3) | NA | NA |
Anti-CCP-positive, n (%) | 26 (83.9) | NA | NA |
DAS28, median (IQR) | 5.78 (4.83 to 6.39) | NA | NA |
Previous medications, n (%) | Â | NA | NA |
Corticosteroids | 12 (38.7) | NA | NA |
Methotrexate | 12 (38.7) | NA | NA |
Leflunomide | 5 (16.1) | NA | NA |
Sulfasalazine | 1 (3.2) | NA | NA |
Hydroxychloroquine | 3 (9.7) | NA | NA |
Etanercept | 3 (9.7) | NA | NA |